News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Connie Chen

Articles by Connie Chen

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Doris Makari,Rachel M. Layman,Hope S. Rugo, MD

August 20th 2024

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

ByGabrielle Rocque,Joanne L. Blum, MD, PhD,Yan Ji,Eric Gauthier,Yao Wang,Monica Z. Montelongo,Joseph C. Cappelleri,Connie Chen,Meghan S. Karuturi,Debu Tripathy, MD

July 24th 2024

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M. Layman,Hope S. Rugo, MD

April 28th 2023

Latest Updated Articles

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above
Published: April 28th 2023 | Updated:

Trending on CancerNetwork

How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma

Should Those with Non-Hodgkin Lymphoma Receive CAR T or Bispecifics?

Leveraging Novel Software to Further Improve Personalized Cancer Care

© 2025 MJH Life Sciences^®

All rights reserved.